NCT00833235

Brief Summary

This is a multi-center, prospective, controlled, observational study of the natural history of patients with dry eye disease.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
284

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Feb 2009

Longer than P75 for all trials

Geographic Reach
1 country

17 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 30, 2009

Completed
2 days until next milestone

Study Start

First participant enrolled

February 1, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

February 2, 2009

Completed
8.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 6, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 6, 2017

Completed
Last Updated

July 25, 2017

Status Verified

July 1, 2017

Enrollment Period

8.1 years

First QC Date

January 30, 2009

Last Update Submit

July 22, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • Percentage of Patients with Progression of Dry Eye Disease

    Baseline, 60 Months

Secondary Outcomes (5)

  • Change from Baseline in Ocular Surface Disease Index© (OSDI©) Score

    Baseline, 60 Months

  • Percentage of Patients with an Increase in Blurred Vision

    Baseline, 60 Months

  • Change from Baseline in Schirmer's Test

    Baseline, 60 Months

  • Change from Baseline in Conjunctival Staining Score on a 6-Point Scale

    Baseline, 60 Months

  • Change from Baseline in Corneal Staining Score on a 6-Point Scale

    Baseline, 60 Months

Study Arms (2)

Patients with dry eye

No treatment is prescribed for the study. Patient dry eye progression will be followed for up to 60 months. Patients may use artificial tears to treat their dry eye symptoms.

Other: Artificial Tears

Patients with no history of dry eye

No treatment is prescribed for this control group. Patients will be followed for up to 60 months. If needed, patients may use artificial tears.

Other: Artificial Tears

Interventions

Artificial tears (any brand) may be used to treat dry eye symptoms.

Patients with dry eyePatients with no history of dry eye

Eligibility Criteria

Age40 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

At least 200 dry eye patients (with at least 40% of patients with elevated biomarkers for ocular surface inflammation) will be enrolled at approximately 15-20 sites. Approximately 40-50 patients will be enrolled in the control group.

You may qualify if:

  • Males at least 55 years old or females, at least 40 years old with perimenopausal symptoms
  • Baseline OSDI score of ≥ 13
  • Patients with mild to moderate dry eye (dry eye disease patients only; not applicable for control group)

You may not qualify if:

  • Use of any topical cyclosporine ophthalmic emulsion within 3 months of baseline
  • History of herpes keratitis or varicella zoster keratitis
  • Any history of allergic conjunctivitis
  • Temporary or permanent occlusion or cauterization of the lacrimal puncta for either eye
  • Any anterior segment surgery involving a limbal or corneal incision (cataract surgery), keratorefractive procedure (LASIK, LASEK, PRK) within 12 months of baseline, or expectation of such surgery within 2 years
  • Patients with known systemic disease
  • Any history of corneal transplant

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (17)

Jones Eye Institute

Little Rock, Arkansas, 72205, United States

Location

North Valley Eye Medical Group, Inc.

Mission Hills, California, 91345, United States

Location

Milauskas Eye Institute

Rancho Mirage, California, 92270, United States

Location

Eye Center of Northern Colorado

Fort Collins, Colorado, 80525, United States

Location

Cape Coral Eye Center, PA

Cape Coral, Florida, 33904, United States

Location

The Eye Institute of West Florida

Largo, Florida, 33770, United States

Location

The Wilmer Eye Institute Johns Hopkins Hospital

Baltimore, Maryland, 21287, United States

Location

Minnesota Eye Consultants, P.A.

Bloomington, Minnesota, 55431, United States

Location

Mulqueeny Eye Centers

Creve Coeur, Missouri, 63141, United States

Location

Mercy Eye Specilaists

Springfield, Missouri, 65804, United States

Location

Cleveland Eye Clinic

Brecksville, Ohio, 44141, United States

Location

Ophthalmic Partners Bala

Cynwyd, Pennsylvania, 19004, United States

Location

Hazleton Eye Specialists

Township, Pennsylvania, 16066, United States

Location

Vanderbilt Eye Institute

Nashville, Tennessee, 37232, United States

Location

Alkek Eye Center, Department of Ophthalmology

Houston, Texas, 77030, United States

Location

The Eye Clinic of Texas/ dba Texas Clinical Eye Research Center

League City, Texas, 77573, United States

Location

See Clearly Vision Group

McLean, Virginia, 22102, United States

Location

Related Publications (1)

  • McDonnell PJ, Pflugfelder SC, Stern ME, Hardten DR, Conway T, Villanueva L, Hollander DA. Study design and baseline findings from the progression of ocular findings (PROOF) natural history study of dry eye. BMC Ophthalmol. 2017 Dec 28;17(1):265. doi: 10.1186/s12886-017-0646-5.

Biospecimen

Retention: SAMPLES WITH DNA

Tear collection

MeSH Terms

Conditions

Dry Eye Syndromes

Interventions

Lubricant Eye Drops

Condition Hierarchy (Ancestors)

Lacrimal Apparatus DiseasesEye Diseases

Intervention Hierarchy (Ancestors)

Ophthalmic SolutionsPharmaceutical SolutionsSolutionsPharmaceutical PreparationsTherapeutic UsesPharmacologic ActionsChemical Actions and UsesLubricantsSpecialty Uses of Chemicals

Study Officials

  • Tes Ignacio

    Allergan

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 30, 2009

First Posted

February 2, 2009

Study Start

February 1, 2009

Primary Completion

March 6, 2017

Study Completion

March 6, 2017

Last Updated

July 25, 2017

Record last verified: 2017-07

Locations